Study Highlights Benefits of Tumour Gene Profiling for Advanced Cancer Patients

Introduction to Targeted Drugs

A recent study by physicians at the Cancer Treatment Centres of America indicates that tumour gene profiling can significantly benefit patients with advanced cancer. Targeted drugs are a specific class of anti-cancer medications designed to align with the unique genetic makeup of a patient’s tumour. By detecting mutations in tumour genes through profiling, clinicians can select targeted treatments that correspond to the DNA alterations present.

Impact of Community Practice on Treatment

Most patients with advanced cancer receive treatment in community practice settings. Current statistics reveal that approximately 25% of individuals with advanced cancer treated at Comprehensive Cancer Care Network centres in the United States utilize this approach. Expanding the application of targeted drugs in community practice could enhance accessibility for patients, ultimately reshaping the landscape of advanced cancer treatment in these settings.

Research Findings

In this extensive study, researchers examined tumour DNA from over 6,000 patients with advanced cancer. The most prevalent cases involved patients with advanced breast, colorectal, lung, and gynecological cancers. The analysis uncovered genetic mutations in 94% of the samples; however, only 47% of these mutations were deemed clinically significant. Following this, 23% of patients were prescribed a genomically-matched treatment. These findings were shared on October 20th at the European Society for Medical Oncology 2018 congress in Munich, Germany.

Challenges with Targeted Therapy

Despite the promise of this innovative approach, the cost associated with genomic analysis poses a significant challenge. Patients whose tumours do not respond to conventional anti-cancer therapies are candidates for tumour gene profiling, requiring a biopsy to gather the necessary cells for analysis. The samples are then sent to a laboratory, with results typically available within three weeks. This selection process for targeted therapy can be time-consuming, and substantial funding is necessary to provide genomic analyses for the large patient population with advanced cancer.

Need for Standardization

The implementation of this treatment strategy is not yet standardized. Clinical trials have revealed variability in matching tumour genetic profiles to targeted therapies, highlighting the need for a more simplified and consistent approach. While targeted therapies are becoming increasingly popular due to their effectiveness in treating advanced cancer, further improvements are essential before full integration into community practice can be achieved.

Conclusion and Future Directions

The potential of targeted therapies to provide more effective treatment for advanced cancer is evident; however, several enhancements are required to facilitate their widespread adoption in community settings. Ongoing research is necessary to standardize and simplify the processes involved in tumour gene profiling and targeted therapy to ensure that patients receive optimal care.

References

European Society of Medical Oncology. Targeted drugs for advanced cancer move from specialist units to community setting. Press Release. October 9, 2018. https://www.esmo.org/Press-Office/Press-Releases/Mutations-sequencing-cancer-AlvarezAlvarez RH, Moran A, Mein E, et al. Mutational landscape of metastatic cancers discovered from prospective clinical sequencing at community practice cancer program. [abstract]. ESMO 2018 Congress. October 20, 2018.